Emerging research suggest Retatru tide , a dual stimulator targeting both incretin and GIP , appears to represent a significant step forward for body management . Preliminary clinical tests have shown substantial reductions in abdominal tissue, potentially exceeding other body composition medications . Nevertheless , more assessment is required to